Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOHé study).
Fiche publication
Date publication
novembre 2018
Journal
BMC cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr EYMARD Jean-Christophe, Dr PREVOST Alain
Tous les auteurs :
Roché H, Eymard JC, Radji A, Prevost A, Diab R, Lamuraglia M, Soumoudronga RF, Gasnereau I, Toledano A
Lien Pubmed
Résumé
The ZOHé study was a prospective, non-interventional, multicentre study in France to assess the use of biosimilar filgrastim Zarzio® (Sandoz filgrastim) in routine clinical practice in patients at risk of neutropenia-inducing chemotherapy (CT).
Mots clés
Biosimilar pharmaceuticals, Chemotherapy, Febrile neutropenia, Filgrastim, Guidelines recommendations, Observational study, Real-world, Solid tumours
Référence
BMC Cancer. 2018 Nov 16;18(1):1127